PD-L1 CPS é um escore contínuo de IHC usado como limiar de elegibilidade para ICI contendo r...
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
| ID | BMA-PDL1-CPS-GASTRIC |
|---|---|
| Tipo | Relevância terapêutica |
| Estado | reviewed 2026-05-07 | actionability review required |
| Doenças | DIS-GASTRIC |
| Fontes | SRC-CHECKMATE-649-JANJIGIAN-2022 SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Fatos de ação
| Biomarcador | BIO-PDL1-CPS |
|---|---|
| Doença | DIS-GASTRIC |
| Nível ESCAT | IA |
| Combinações recomendadas | nivolumab + fluoropyrimidine + platinum (CPS≥5, 1L per SRC-NCCN-GASTRIC-2025, SRC-ESMO-GASTRIC-2024), nivolumab + FOLFOX/XELOX (CPS≥1 broader population per SRC-CHECKMATE-649-JANJIGIAN-2022) |
| Resumo das provas | PD-L1 CPS is a continuous IHC score used as an eligibility threshold for ICI-containing regimens in metastatic gastric/GEJ adenocarcinoma. Thresholds vary by regimen: CPS ≥5 — nivolumab + fluoropyrimidine + platinum (CheckMate-649; mOS 14.4 vs 11.1 mo, HR 0.71 in CPS≥5 subgroup); CPS ≥1 — nivolumab + chemo as broader population (CM-649); CPS ≥1 — pembrolizumab + trastuzumab + chemo for HER2+ disease (KEYNOTE-811, covered separately in BMA-HER2-AMP-GASTRIC). Per NCCN and ESMO 2024, PD-L1 CPS testing by IHC 22C3 pharmDx is mandatory prior to 1L treatment selection. Threshold-gated indication selection is performed by the algorithm layer (IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI); this BMA entry surfaces ESCAT tier context for tumor-board discussion only. |
Notas
Variant_qualifier is null (gene-level) — CPS is a continuous score; specific threshold gating (CPS≥5 vs ≥1) is enforced by the indication layer, not this BMA cell. This entry exists to prevent the render layer from showing "Not in KB" for a well-defined, FDA-approved biomarker. KEYNOTE-811 evidence is attributable to BMA-HER2-AMP-GASTRIC to avoid overlap.
Usado por
Não há referências reversas encontradas no corpus YAML.